Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (439)	10/30/1998 9:28:00 AM
From: muddphudd	Read Replies (2) \| Respond to of 586

The issue about sepsis does not sound like a very big deal. Any invasive device (this column can be considered invasive, as is any plasmapheresis) has the risk of infection. How likely that is depends on the technique used and, as they mentioned, the equipment (tubes in this case). Since this column has been around for a decade I am not too concerned about that. If sepsis was a major problem for Prosorba we would have heard about it, it would have been reported (just like the Mayo Clinic pulled the plug on Redux). The problem will be effective marketing and a partner. I hope they announce one soon. If they do not, the price will not hold.

To: Arthur Radley who wrote (439)	10/30/1998 9:44:00 AM
From: John S. Baker	Respond to of 586

"Also, it appears that there might be new products coming on board in the near future. " I have followed CYPB for some time now, and the issue of other products ... chemical drugs ... has been raised before. I personally take some comfort in the fact that CYPB consistently has been very clear in its positioning of the Prosorba column as being indicated only for the most intractable cases ... those for which no chemical treatment has been effective. In other words: for last-ditch use (as in people who otherwise could not walk). And their financial estimates have also been based on such usage. But, as you point out, share prices are often based on perceptions rather than real facts. To that extent, such misperceptions in the market place need to addressed vigorously by CYPB on a steady, ongoing basis. IMHO, management is savvy enough to realize this. JSb.